Using data pooled from the pivotal RAPID1 and RAPID2 RCTs and OLEs [20–23], we derived and tested a new AACI to predict the risk of SIEs during CZP treatment, based on the baseline characteristics of anti-TNF naive patients with moderate to severe active RA and inadequate response to prior disease-modifying antirheumatic drugs. This evidence concerns the gene TNF and rheumatoid arthritis.